Literature DB >> 10572000

Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs.

A Mancy1, M Antignac, C Minoletti, S Dijols, V Mouries, N T Duong, P Battioni, P M Dansette, D Mansuy.   

Abstract

A comparison of the oxidations of diclofenac with microsomes of yeasts expressing various human liver cytochromes P450 showed that P450 2C9 regioselectively led to 4'-hydroxy diclofenac (4'-OHD) whereas P450 3A4 only led to 5-hydroxy diclofenac (5-OHD). P450 2C19, 2C18, and 2C8 led to the simultaneous formation of 4'-OHD and 5-OHD (respective molar ratios of 1.3, 0.37, and 0.17), and P450 1A1, 1A2, 2D6, and 2E1 failed to give any detectable hydroxylated metabolite under identical conditions. P450 2C9 was found to be much more efficient for diclofenac hydroxylation than all the other P450s tested (k(cat)/K(M) of 1.6 min(-1) microM(-1) instead of 0.025 for the second more active P450), mainly because of markedly lower K(M) values (15 +/- 8 instead of values between 170 and 630 microM). Oxidation of diclofenac with chemical model systems of cytochrome P450 based on iron porphyrin catalysts exclusively led to the quinone imine derived from two-electron oxidation of 5-OHD, in an almost quantitative yield. Two derivatives of diclofenac lacking its COO(-) function were then synthesized; their oxidation by recombinant human P450 2Cs always led to a major product coming from their 5-hydroxylation. Substrate 2, which derives from reduction of the COO(-) function of diclofenac to the CH(2)OH function, was studied in more detail. All the P450s tested (1A1, 1A2, 2C8, 2C9, 2C18, 2C19, 2D6, and 3A4) almost exclusively led to its 5-hydroxylation. P450s of the 2C subfamily were found to be the most efficient catalysts for this reaction, with k(cat)/K(M) values between 0.2 and 1.6 min(-1) microM(-1). Oxidation of 2 with an iron porphyrin-based chemical model of cytochrome P450 also led to a product derived from the oxidation of 2 at position 5. These results show that oxidation of diclofenac and its derivative 2, either with chemical model systems of cytochrome P450 or with recombinant human P450s, generally occurs at position 5. This position, para to the NH group on the more electron-rich aromatic ring of diclofenac derivatives, is thus, as expected, the privileged site of reaction of electrophilic, oxidant species. The most spectacular exception to this chemoselective 5-oxidation of diclofenac derivatives was found for oxidation of diclofenac itself with P450 2C9 (and P450 2C19 and 2C18 to a lesser extent), which only led to 4'-OHD. A likely explanation for this result is a strict positioning of diclofenac in the P450 2C9 active site, via its COO(-) function, to completely orientate its hydroxylation toward position 4', which is not chemically preferred. P450 2C19, 2C18, and 2C8 would not lead to such a strict positioning as they give mixtures of 4'-OHD and 5-OHD. The above results show that diclofenac derivatives are interesting tools to compare the active site topologies of human P450 2Cs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10572000     DOI: 10.1021/bi991195u

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

Review 1.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

2.  Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity.

Authors:  Jack U Flanagan; Lesley A McLaughlin; Mark J I Paine; Michael J Sutcliffe; Gordon C K Roberts; C Roland Wolf
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

3.  Establishment of a transgenic cell line stably expressing human cytochrome P450 2C18 and identification of a CYP2C18 clone with exon 5 missing.

Authors:  Jian Zhu-Ge; Ying-Nian Yu; Yu-Li Qian; Xin Li
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

4.  The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.

Authors:  Carmen Martínez; Elena García-Martín; Gerardo Blanco; Francisco J G Gamito; José M Ladero; José A G Agúndez
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

5.  Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2.

Authors:  Pierre Lafite; Sylvie Dijols; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy
Journal:  Arch Biochem Biophys       Date:  2007-04-10       Impact factor: 4.013

6.  Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.

Authors:  Julia Kirchheiner; Ingolf Meineke; Nadine Steinbach; Christian Meisel; Ivar Roots; Jürgen Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

7.  Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2.

Authors:  Pierre Lafite; Sylvie Dijols; Didier Buisson; Anne-Christine Macherey; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy
Journal:  Bioorg Med Chem Lett       Date:  2006-02-21       Impact factor: 2.823

8.  Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.

Authors:  David J Elliot; Benjamin C Lewis; Elizabeth M J Gillam; Donald J Birkett; Annette S Gross; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2007-05-22       Impact factor: 4.335

9.  Quantum mechanics/molecular mechanics modeling of regioselectivity of drug metabolism in cytochrome P450 2C9.

Authors:  Richard Lonsdale; Kerensa T Houghton; Jolanta Żurek; Christine M Bathelt; Nicolas Foloppe; Marcel J de Groot; Jeremy N Harvey; Adrian J Mulholland
Journal:  J Am Chem Soc       Date:  2013-05-16       Impact factor: 15.419

Review 10.  Optimization of the bacterial cytochrome P450 BM3 system for the production of human drug metabolites.

Authors:  Giovanna Di Nardo; Gianfranco Gilardi
Journal:  Int J Mol Sci       Date:  2012-11-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.